CORE
🇺🇦Â
 make metadata, not war
Services
Services overview
Explore all CORE services
Access to raw data
API
Dataset
FastSync
Content discovery
Recommender
Discovery
OAI identifiers
OAI Resolver
Managing content
Dashboard
Bespoke contracts
Consultancy services
Support us
Support us
Membership
Sponsorship
Community governance
Advisory Board
Board of supporters
Research network
About
About us
Our mission
Team
Blog
FAQs
Contact us
Filters
11 research outputs found
The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection
Author
ENCORE1 Study Group
Gueorgui Dubrocq
+3Â more
Natella Rakhmanina
Rakhmanina N Van Den Anker J
Swartz JE
Publication venue
'Informa UK Limited'
Publication date
Field of study
No full text
Crossref
Darunavir/ritonavir 600/100 mg once daily: it’s time for larger non-inferiority randomized trials
Author
Clotet
Dierynck
+14Â more
E Concia
E Lattuada
ENCORE1 Study Group
F Rigo
G Cucchetto
Katlama
Lanzafame
M Lanzafame
Molina
Molto
Orkin
S Nicolè
Seang
Young
Publication venue
'Oxford University Press (OUP)'
Publication date
Field of study
No full text
Crossref
Safety of zidovudine dose reduction in treatment-naïve HIV infected patients. A randomized controlled study (MiniZID)
Author
Camponeschi
Crawford
+22Â more
Duncombe
ENCORE1 Study Group
Gallant
Hamers
Hill
Hoffmann
Kumarasamy
Li
Makubi
Margot
Markowitz
Moh
Monleau
Moyle
Murphy
Nachega
Phanuphak
Ssali
UNAIDS
Velen
White
WHO
Publication venue
'Wiley'
Publication date
Field of study
No full text
Crossref
Effectiveness of half-a-tablet efavirenz plus 2 nucleos(t)ide reverse-transcriptase inhibitors as maintenance therapy with the guidance of therapeutic drug monitoring among virologically suppressed HIV-positive patients: A prospective study
Author
BREATHER (PENTA 16) Trial Group
Carey
+29Â more
Cohen
Csajka
Dickinson
Dickinson
ENCORE1 Study Group
Fayet Mello
Figueroa
Gatanaga
Gutiérrez
Huang
Kanters
Lanzafame
Lanzafame
Lee
MartÃn
Marzolini
Mills
Mukonzo
Orrell
Pozniak
Rojas
Russo
Scourfield
Siccardi
Sinxadi
van Luin
World Health Organization
World Health Organization
Wu
Publication venue
'Elsevier BV'
Publication date
Field of study
No full text
Crossref
Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic–Pharmacogenetic Model of HIV-infected Patients in Thailand
Author
Anchalee Avihingsanon
Arab-Alameddine
+48Â more
Avihingsanon
Baralee Punyawudho
Bergstrand
Cabrera
Cabrera Figueroa
Clifford
Csajka
Davaalkham
Department of Disease Control
Dhoro
Dickinson
ENCORE1 Study Group
Ette
Fayet Mello
Gallien
Gatanaga
Group
Guan
Guan
Haas
Hui
Kappelhoff
Kwara
Lang
Leger
Lopez-Cortes
Manosuthi
Manosuthi
Marzolini
Matteelli
Meng
Mukonzo
Ngaimisi
Nyakutira
Pfister
Piyawat Chaivichacharn
Robarge
Sanchez
Sasiwimol Ubolyam
Siraprapa Tongkobpetch
Soeria-Atmadja
Sukasem
Sukasem
Sukasem
To
Uttayamakul
Vorasuk Shotelersuk
Weerawat Manosuthi
Publication venue
'Elsevier BV'
Publication date
Field of study
No full text
Crossref
Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition
Author
Abdelhady
Almond
+69Â more
Anderson
Anderson
Aouri
Arab-Alameddine
Avery
Balani
Beal
Belanger
Bristol-Myers Squibb Company
Cabrera
Cho
Cho
Cristofoletti
Csajka
de Roche
Desta
Dhoro
di Iulio
Elzi
ENCORE1 Study Group
Gao
Gutierrez-Valencia
Haas
Haas
Han
Holford
Honorio Tda
Horter
Ingrid F. Metzger
Itoh
Janmahasatian
Jason D. Robarge
Jessica Lu
Kappelhoff
Kappelhoff
Keizer
Lamba
Lamorde
Lang
Leutscher
Li
Lindbom
Marzolini
Marzolini
McDonagh
Michaud
Michaud
Mukonzo
Mukonzo
Mutlib
Nancy Thong
Ngaimisi
Ngaimisi
Ogburn
Puls
R Development Core Team
Robert R. Bies
Rotger
Salem
Sanchez
Sanchez Martin
Savic
Swart
Todd C. Skaar
Wagner
Ward
West
Zanger
Zeruesenay Desta
Publication venue
'American Society for Microbiology'
Publication date
Field of study
No full text
Crossref
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
Author
A Olagunju
A Olagunju
+45Â more
A Olagunju
A Schipani
AA Motsinger
AF Luetkemeyer
Amanda Clarke
Andrew Owen
BA Ward
C Cordon-Cardo
C Csajka
C Marzolini
C Marzolini
C Wyen
Catherine Orrell
David A. Cooper
David Back
Deirdre Egan
Dianne Carey
DS Lehmann
E Ngaimisi
E Stormer
ENCORE1 Study Group
ER Holzinger
FV Leth
G Dirson
IH Bartelink
J Lamba
Janaki Amin
JE Gallant
JM Rae
KE Dooley
L Dickinson
Laura Dickinson
Laura Else
LB Tovar-y-Romo
M Siccardi
Marcelo Losso
Marta Boffito
Praphan Phanuphak
R Puls
RB Kim
Rebekah Puls
Saye Khoo
Sean Emery
TR Cressey
TR Glass
Publication venue
'Springer Science and Business Media LLC'
Publication date
Field of study
No full text
Crossref
Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug–drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART
Author
Andrew Owen
Bayer New Zealand Limited
+60Â more
Bosgra
Bowman
Carten
Chappell
Courtney V Fletcher
Curtis
David J Back
Duvall
EMA
ENCORE1 Study Group
FDA
FDA
Fowler
Gertz
Gipson
Gupta
Hariparsad
Hubacher
Jacobstein
Jamei
Jones
Jones
Kimberly K Scarsi
Kook
Kristin M Darin
Kwara
Marco Siccardi
Marzolini
Mohammed Lamorde
Moss
Mouly
Nanda
National Center for Biotechnology Information
Neary
NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development
Owain Roberts
Patel
Perry
Petruney
Polis
Poulin
Rajith K R Rajoli
Rajoli
Reitter
Robinson
Rotger
Rowland
Scarsi
Scarsi
Siccardi
Tseng
Vieira
Ward
WHO
WHO
WHO
WHO
WHO
Yu
Zhuang
Publication venue
'Oxford University Press (OUP)'
Publication date
Field of study
No full text
Crossref
A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400Â mg in Pregnant Women
Author
A Nakai
A Olagunju
+53Â more
AG Dosne
Alwin D. R. Huitema
Angela C. Colbers
BL Jilek
Brookie M. Best
BS Kappelhoff
BS Kappelhoff
C Marzolini
C Orrell
C Sukasem
C Vong
DA Chiappetta
David M. Burger
E Comets
E Svensson
Edmund Capparelli
EM Gilbert
ENCORE1 Study Group
EP Acosta
ER Holzinger
F Leth Van
Frans G. M. Russel
G Maartens
GB West
HH Semvua
J Tarning
K Abduljalil
K Brendel
KC Carlsson
KE Dooley
Kelly E. Dooley
L Dickinson
LB Avery
LB Avery
LJ Dickmann
M Dawes
M Rotger
Mark Mirochnick
Paolo Denti
PL Toutain
Rick Greupink
RJ Keizer
RJ Keizer
RJ Keizer
Rob ter Heine
S Schalkwijk
S Zheng
Stein Schalkwijk
T Gordi
Tim R. Cressey
TM Hu
TR Cressey
V Gounden
Publication venue
'Springer Science and Business Media LLC'
Publication date
Field of study
No full text
Crossref
Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study
Author
A Diallo
A Rami
+71Â more
A Simon
Arab-Alameddine
Boffito
Bunupuradah
C Allavena
C Duvivier
C Lascoux
Christine Katlama
Costagliola
D Loreillard
D Ponscarme
Dickinson
E Billaud
E M B El Abassi
El Mountacer Billah El Abbassi
EMA
ENCORE1 Study Group
F Raffi
François Raffi
French National Guidelines
G Gras
G Gras
G Peytavin
G Point
Gilles Peytavin
I Charreau
I Madelaine
I Poizot-Martin
J M Molina
J Saillard
Jean-Michel Molina
Julie Bertrand
Juliette Saillard
Jung
Kakuda
Katlama
Kearney
Kiser
L Bernard
L Bocquet
Lê
M L Chaix
Marie-Laure Chaix
Marzolini
Minh P Lê
Molina
Moltó
Moltó
N Hall
Ortiz
P De Truchis
P M Girard
P Tattevin
Pierre Delobel
R Tubiana
Rittweger
S Bouchez
S Chevret
S Couffin-Cadiergues
S Gallien
S Gibowski
Singer
Sylvie Chevret
Sébastien Gallien
V Jeantils
V Lemoing
V Reliquet
Valade
Waters
Y Yazdanpanah
Yazdan Yazdanpanah
Publication venue
'Oxford University Press (OUP)'
Publication date
Field of study
No full text
Crossref
1
2